Immuron Limited (IMRN)

[Triple nickle]

Here we gooooo

[Pisd]

Gonna hold on here.. IMRN$...

[knrorrel]

IMRN good News Out running hard

imho

[Pisd]

Finally something going up.. IMRN$...

[subslover]

That's great news! Thanks.

[tw0122]

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

Source: GlobeNewswire Inc.

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that the US Naval Medical Research Center (NMRC) has received approval from the US Food and Drug Administration (FDA) to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhoea cause

[DK11]

https://www.sec.gov/Archives/edgar/data/1660046/000121390023012017/ea173668ex99-1_immuron.htm
I guess for those who Travel a lot, some relief.

[THEMASTERS_SON]

…skip

[THEMASTERS_SON]

,,,,,,,We’ll break $3 shortly! FASHOO!!!

[THEMASTERS_SON]

,,,,,,,COVER YOU MORONS WEEEEEE!

[TheFinalCD]

https://finviz.com/quote.ashx?t=IMRN&p=d

[THEMASTERS_SON]

,,,,,,,SUPER CHEAP

[TheFinalCD]

thanks for the heads up

[subslover]

Immuron Receives FDA Approval for Travelan IND Application
December 23 2022 - 06:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that it has received approval from the US Food and Drug Administration to proceed with the clinical evaluation of Travelan. The Investigational New Drug (IND) application to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active.
As a result of this approval the company will proceed with the planned clinical trial in the United States. The safety and protective efficacy of Travelan will be tested utilizing a controlled human infection-model clinical trial design.

Immuron is the sponsor of the IND, and the clinical study will be conducted by the Contract Research Organisation Pharmaron CPC, Inc (ASX announcement October 4, 2022) at its FDA inspected clinical research facility located in Baltimore, Maryland in the USA.

The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan® in a controlled human infection model (CHIM) using the enterotoxigenic Escherichia coli (ETEC) strain H10407. The clinical study aims to enrol up to 60 healthy adult subjects each will be randomly assigned to receive either a once-daily dose of 1200 mg of Travelan® (30 subjects) or placebo (30 subjects). Recruitment is planned to be initiated in 1H 2023 with headline results from the clinical trial expected to be reported by year end 2023.

Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. The morbidity and associated discomfort stemming from diarrhea decreases daily performance, affects judgment, decreases morale and declines operational readiness. The first line of treatment for infectious diarrhea is the prescription of antibiotics. Unfortunately, in the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics. In addition, travelers' diarrhea is now recognized by the medical community to result in post-infectious sequelae, including post-infectious Irritable Bowel Syndrome and several post-infectious autoimmune diseases. A preventative treatment that protects against enteric diseases, is a high priority objective for the US Military.

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT:

Steven Lydeamore
Chief Executive Officer
Ph: [phone]
[e-mail]

For more information visit: http://www.immuron.com



Primary Logo

Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Immuron Charts. Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Immuron Charts.

[Soulman856]

Making a run here today

[Tim]

Nice:
Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on April 27, 2022 titled:

- “Immuron Q3 Global Sales up 216% YoY”

[Man6677]

Thank you !

[Pisd]

btw Immuron warrants expire May 12th ..$10 gl...

[Man6677]

I think IMRN is a good buy here .

GLTA !

[Pisd]

Maybe they learned a lesson?..develop Covid pill lol IMRN$..

[Pisd]

Sold when director left $4.70..buyer today $3.55 IMRN$...

[Pisd]

Covid pill in development same as RVVTF$, gl...

[Pisd]

Quiet here, good! ..waiting IMRN$...

[Pisd]

Everybody asleep here..one day get woken up imo.. IMRN/W$...

[Pisd]

A gift at $5.20 today.. total sleeper atm.. IMRN$...

[Pisd]

https://www.wsj.com/articles/next-generation-of-covid-19-vaccines-could-be-pill-or-spray-11620034381?siteid=yhoof2&yptr=yahoo

[Pisd]

Reiterate..holding IMRN$$..covid pill, travelers disease..etc might add $5ish, gl...

[Pisd]

...please tell

[calculatedrisk]

JUST LOADED UP ON THIS ONE....NEWS IMMINENT....$18-$22 BY EOW

[Pisd]

Vaxart huge pop/drop..covid pill vaccine.. real deal here IMRN$...

[Pisd]

This ticker lies dormant until the aftermarket PR.. IMRN$...

[Pisd]

Awesome pill for gut diseases likely COVID killer.. IMRN$...

[Pisd]

Immuron PR Confirms Co. Recently Executed SARS-CoV-2 Research Services Agreement With Monash University To evaluate IMM-124E

6:52 am ET December 15, 2020 (Benzinga) Print


Immuron's Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies.


A
Immuron's Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies.


A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron's marketed products (IMM-124E).


MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of the anti-viral activity of IMM-124E. The company has been actively engaging with local, national, and international research collaborators to advance this work and assist in the further characterization of the neutralization activity of SARS-CoV-2 observed with Immuron's commercial hyper-immune colostrum used to manufacture the company's flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn®.

The company has recently executed a new Research Agreement with Monash University to develop new assays to evaluate the efficacy of IMM-124E, the active pharmaceutical ingredient used to manufacture Travelan® and Protectyn® to further our understanding of the inhibitory substance/s in our commercial products.

The research team will be led by Dr Melanie Hutton and Professor Dena Lyras, Deputy Director, Biomedicine Discovery Institute and Deputy Head, Department of Microbiology who will utilize two new recombinant reagents, the SARS-CoV-2 Spike protein, a receptor binding domain protein as well as an antibody positive human serum sample obtained from Melbourne's Peter Doherty Institute for Infection and Immunity.

"We have been very fortunate to obtain access to the SARS-CoV-2 recombinant proteins developed at the Peter Doherty Institute for Infection and Immunity," said Professor Lyras. "These reagents will be used to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E. Furthermore, specific immune components will be purified from IMM-124E and will be used to evaluate their ability to inhibit the binding of an antibody positive human serum sample to specific COVID-19 proteins, such as the spike protein which is crucial for cell entry," said Dr Hutton.

This release has been authorised by the directors of Immuron Limited.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[ClayTrader]

* * $IMRN Video Chart 11-11-2020 * *

Link to Video - click here to watch the technical chart video

[TheFinalCD]

IMRN 8.31

[Pisd]

Peeps forgot story here/moved on, not me.. patient IMRNW...

[Pisd]

Buyer most I can get IMRNW..only $1 bid gl...

[Pisd]

Holding free shares here, story is unchanged IMRN$ IMRNW$...

[Pisd]

IMRNW$..bid/ask under $2? what a great lottery ticket imo...

[Pisd]

5.5 M shares outstanding IMRN$$ ...

[Pisd]

Waiting on update covid19 vaccine PILL, also progress on drug in studies with the government funding. There are no existing cures for intestinal disorders soldiers traveling to different countries get. Imagine multiplier to include all people in the world for that? I think 4M only shares outstanding..

IMRN$$..

[Dubster watching]

Considering getting more but need 1 or 2 more reasons atm

[RealPainkiller]

I love this stock I already made profits 10 fold on it's previous run before the last. I held some all the way down to 5.90 or wherever it was. obviously it paid off again..

[Dubster watching]

Not down from where I purchased shares.
$11.45 at close
Day high $12.67
Day low $11

I’m green.

[RealPainkiller]

It's down what are you talking about?

[Dubster watching]

Loaded some shares and slightly green. Looks like the right spot.

[Pisd]

Today need HUGE news every 3_days keep peeps attention-span...

[Pisd]

IMRNW$ increase a dollar as does common $4-$5-$6 etc...

[Pisd]

...approximately seventy to eighty percent of your immune tissue is located within your digestive system? The gut is often the first entry point for exposure to pathogens (bad bacteria and virus’ that can cause disease)...

Children raised by wolves know the modern diet causes leaky gut and related illnesses taxing human immune system including viruses, diseases; the blood carries pathogens throughout the body etc.

https://www.foodmatters.com/article/your-gut-and-immune-system-connection-recipe-giveaway

IMRN$$

[Pisd]

Double's good?, still just getting started; COVID play.. IMRN$$...